Zoetis Inc. (LON:0M3Q)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 55.22B |
| Revenue (ttm) | 7.19B |
| Net Income (ttm) | 1.95B |
| Shares Out | n/a |
| EPS (ttm) | 4.31 |
| PE Ratio | 28.33 |
| Forward PE | 26.54 |
| Dividend | 1.45 (0.86%) |
| Ex-Dividend Date | Apr 21, 2025 |
| Volume | 2,787 |
| Average Volume | 6,072 |
| Open | 168.41 |
| Previous Close | 169.50 |
| Day's Range | 168.18 - 169.86 |
| 52-Week Range | 139.92 - 200.19 |
| Beta | 0.94 |
| RSI | 60.57 |
| Earnings Date | Aug 5, 2025 |
About Zoetis
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph... [Read more]
Financial Performance
In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.
Financial numbers in USD Financial StatementsNews
Zoetis Releases 2024 Sustainability Progress Update
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis published its 2024 Sustainability Progress Update “Advancing Sustainability in Animal Health for a Better Future” to highlight the comp...
Zoetis Inc. (ZTS) William Blair 45th Annual Growth Stock Conference (Transcript)
How pet medicine stocks could cushion your healthcare investments from Trump changes
Moderna shares are seeing a boost on Monday after the US Food and Drug Administration (FDA) gave the pharmaceutical giant limited approval for its lower-dose COVID-19 vaccine. Morgan Stanley Investmen...
Top 15 High-Growth Dividend Stocks For June 2025
My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in May, gaining 6.45% versus SPY's 6.28% and VIG's 3.61%. The list's year-to-date return is 6.07%, beating SPY every month in 2025, thoug...
Zoetis Inc. (ZTS) Stifel 2025 Jaws & Paws Conference (Transcript)
Dr. Mark Stetter Elected to Zoetis Board of Directors
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company's annual share...
Zoetis Declares Third Quarter 2025 Dividend
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the third quarter of 2025. The dividend will b...
Lightning Round: Mosaic is up too much, don't buy here, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: DeFi Technologies, ESCO Technologies, ZIM Integrated Shipping, Mosaic, and Zoetis.
Zoe supplement ad banned over ultra-processed claims
The ASA said the ad for Daily30+ was likely to mislead consumers by implying that the product did not contain any ultra-processed ingredients.
A Look Into Zoetis Inc's Price Over Earnings
In the current market session, Zoetis Inc. (NYSE: ZTS) share price is at $161.01, after a 1.25% decrease. Over the past month, the stock increased by 8.79% , but over the past year, it actually fell ...
Zoetis to Participate in Upcoming Investor Conferences
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the following investor conferences. BNP Pari...
Trade Tracker: Brenda Vingiello sells Zoetis and buys Quanta Services
Brenda Vingiello, Chief Investment Officer at Sand Hill Global Advisors, joins 'Halftime Report' to detail her latest trades.
Trade Tracker: Brenda Vingiello sells Zoetis and buys Quanta Services
Brenda Vingiello, Chief Investment Officer at Sand Hill Global Advisors, joins 'Halftime Report' to detail her latest trades.
Zoetis' Q1: Market Overreaction Or Justified Drop?
Zoetis: Solid Q1 Results And A Weaker Dollar Provide Support (Upgrade)
Zoetis shifts from sell to hold as solid earnings, strong balance sheet, and tailwinds like a weaker dollar suggest fair value and potential 8%+ returns.
Zoetis domestically manufactures 75% of its U.S. sales, says CEO Kristin Peck
Kristin Peck, Zoetis CEO, joins 'Closing Bell Overtime' to talk quarterly results, the animal health sector, raising its guidance, and more.
Zoetis domestically manufactures 75% of its U.S. sales, says CEO Kristin Peck
Kristin Peck, Zoetis CEO, joins 'Closing Bell Overtime' to talk quarterly results, the animal health sector, raising its guidance, and more.
Zoetis maintains 6%-8% revenue growth guidance for 2025 while targeting double-digit growth in key franchises
Zoetis Inc. (ZTS) Q1 2025 Earnings Call Transcript
Zoetis down despite Q1 beats, boosting 2025 guidance
Zoetis Beats Wall Street Estimates, Revises 2025 Guidance To Include Tariffs Impact
Animal health firm Zoetis Inc (NYSE: ZTS) on Tuesday reported a first-quarter 2025 adjusted EPS of $1.48, up from $1.38 a year ago, beating the consensus of $1.39 . Adjusted net income for the first ...
Zoetis raises forecast for 2025 revenue, profit on weaker US dollar
Animal healthcare company Zoetis on Tuesday raised its forecasts for annual adjusted profit and revenue above Wall Street expectations, after beating first-quarter estimates, benefiting from a weak U....
Zoetis Inc. 2025 Q1 - Results - Earnings Call Presentation
Zoetis Non-GAAP EPS of $1.48 beats by $0.08, revenue of $2.2B beats by $10M
Zoetis Announces First Quarter 2025 Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2025 and updated its full year 2025 guidance. The company...